Search research articles
Contact Us
Filters
Showing results (101-110 of 128) with videos related to
Page
of 13
Sort By:
European Urology Focus
|
July 30, 2017
Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review
Pierre-Jean Lamy, Yves Allory, Anne-Sophie Gauchez, et al.
Future Oncology (London, England)
|
April 29, 2024
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer
Yohann Loriot, Arash Rezazadeh Kalebasty, Aude Fléchon, et al.
Bulletin Du Cancer
|
November 26, 2015
[Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria]
Vincent Launay-Vacher, Nicolas Janus, Philippe Beuzeboc, et al.
European Urology
|
November 18, 2021
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial
Giulia Baciarello, Remy Delva, Gwenaelle Gravis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 30, 2021
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
Scott T Tagawa, Arjun V Balar, Daniel P Petrylak, et al.
Clinical Genitourinary Cancer
|
March 23, 2021
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study
Stéphane Culine, Aude Fléchon, Gwenaelle Gravis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 3, 2014
Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2
Stéphane Oudard, Stéphane Culine, Yann Vano, et al.
European Urology
|
May 20, 2025
Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial
Matthew D Galsky, Michiel S van der Heijden, Thomas Powles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 1, 2024
Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer
Yohann Loriot, Arjun V Balar, Daniel P Petrylak, et al.
Future Oncology (London, England)
|
January 16, 2025
Treatment of advanced urothelial cancer with nivolumab plus chemotherapy versus chemotherapy alone (CheckMate 901 study): a plain language summary
Michiel S van der Heijden, Guru Sonpavde, Thomas Powles, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 128) with videos related to
Sort By:
Page
of 13
European Urology Focus
|
July 30, 2017
Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review
Pierre-Jean Lamy, Yves Allory, Anne-Sophie Gauchez, et al.
Future Oncology (London, England)
|
April 29, 2024
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer
Yohann Loriot, Arash Rezazadeh Kalebasty, Aude Fléchon, et al.
Bulletin Du Cancer
|
November 26, 2015
[Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria]
Vincent Launay-Vacher, Nicolas Janus, Philippe Beuzeboc, et al.
European Urology
|
November 18, 2021
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial
Giulia Baciarello, Remy Delva, Gwenaelle Gravis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 30, 2021
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
Scott T Tagawa, Arjun V Balar, Daniel P Petrylak, et al.
Clinical Genitourinary Cancer
|
March 23, 2021
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study
Stéphane Culine, Aude Fléchon, Gwenaelle Gravis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 3, 2014
Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2
Stéphane Oudard, Stéphane Culine, Yann Vano, et al.
European Urology
|
May 20, 2025
Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial
Matthew D Galsky, Michiel S van der Heijden, Thomas Powles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 1, 2024
Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer
Yohann Loriot, Arjun V Balar, Daniel P Petrylak, et al.
Future Oncology (London, England)
|
January 16, 2025
Treatment of advanced urothelial cancer with nivolumab plus chemotherapy versus chemotherapy alone (CheckMate 901 study): a plain language summary
Michiel S van der Heijden, Guru Sonpavde, Thomas Powles, et al.
Page
of 13